Anti-hCD40L-mIgG2a
-
Cat.code:
mab10-h40l-03
- Documents
ABOUT
Recombinant anti-human CD40L neutralizing antibody
Anti-hCD40L-mIgG2a is a monoclonal antibody (mAb) targeting the human CD40 ligand (CD40L). This mAb specifically blocks the binding between CD40L to its receptor CD40, validated using proprietary CD40L reporter cells.
Anti-hCD40L-mIgG2a was previously extracted from hybridoma cells (clone 13H5). It is now expressed and produced in Chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. This antibody can be used together with HEK-Blue™ CD40L cells for screening and neutralization assays to block CD40L signaling induced by recombinant human CD40L (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct has been verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
CD40 Ligand (CD40L) is a protein that is primarily expressed on activated T cells and is a member of the tumor necrosis factor superfamily. Of note, CD40L, together with its receptor CD40, plays a pivotal role in cellular and humoral immunity.
The hybridoma-derived Anti-hCD40L-IgG (mabg-h40l-3) antibody has been replaced by Anti-hCD40L-mIgG2a (mab10-h40l-03), which is produced by recombinant technology and purified from CHO cells.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
CD40L
Human
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hCD40L-mIgG2a
-
Cat code:mab10-h40l-03
-
Quantity:3 x 100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
CD40 Ligand (CD40L), also known as CD154, TRAP, or gp39, is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) family. It is mainly expressed in CD4+-T cells and interacts with CD40 on antigen-presenting cells to regulate both humoral and cellular immune responses [1-3].
The CD40 cytoplasmic domain binds directly to several TNF receptor-associated factors (TRAFs), and this interaction is thought to initiate CD40 signaling. CD40-mediated signaling results in NF-κB, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) activation. CD40L-CD40 interactions are thought to play an important role in the pathogenesis of many diseases [4, 5].
1. Karnell J.L. et al., 2019. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 141:92-103.
2. Laman J.D. et al., 2017. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 37(2-6):371-420.
3. Elgueta R. et al., 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172.
4. Seijkens T. et al., 2013. CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diabetes and Vascular Disease Research. 10: 115 - 122.
5. Daoussis D. et al., 2004. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol. 11(4):635-41.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
